	US 12,467,924 B2
	Double deamidated form of Bcl-xL is a biomarker of platelet age
Chloé James, Pessac (FR); Florian Beaumatin, Bordeaux (FR); and Muriel Priault, Bordeaux (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANÉ ET DE LA RECHERCHE MÉDICALE, Paris (FR); UNIVERSITÉ DE BORDEAUX, Bordeaux (FR); CHU DE BORDEAUX, Bordeaux (FR); and CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR)
Appl. No. 17/617,617
Filed by INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); UNIVERSITÉ DE BORDEAUX, Bordeaux (FR); CHU DE BORDEAUX, Talence (FR); and CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR)
PCT Filed Jun. 11, 2020, PCT No. PCT/EP2020/066210 § 371(c)(1), (2) Date Dec. 9, 2021, PCT Pub. No. WO2020/249678, PCT Pub. Date Dec. 17, 2020.
Claims priority of application No. 19305750 (EP), filed on Jun. 12, 2019.
Prior Publication US 2022/0236270 A1, Jul. 28, 2022
Int. Cl. G01N 33/569 (2006.01); G01N 33/532 (2006.01)

CPC G01N 33/56966 (2013.01) [G01N 33/532 (2013.01); G01N 2440/16 (2013.01); G01N 2800/222 (2013.01)]

10 Claims

1. A method of treating thrombocytopenia in a subject comprising determining the age of a platelet isolated from the subject's blood, comprising the steps of detecting in said platelet the presence of the an Asn52Asn66 doubly-deamidated form of Bcl-xL; and

(a) determining that the platelet is a young platelet when the presence of said form is not detected and administering a transfusion to the subject;

(b) determining that the platelet is an old platelet when the presence of said form is detected and administering at least one treatment selected from the group consisting of a corticoid, and antibody depletion,

wherein antibody depletion is plasma exchange, plasmapheresis or immunoadsorption.